R&I: Ovarian Cancer Therapeutics in Major Developed Markets

1. Ovarian Cancer Therapeutics in Major Developed Markets to 2020 Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies Publisher: GBI Research No of pages: 148 Publish Date: Nov 2014

2. Description GBI Research, has released the pharma report -"Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.

3. Description The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. However, efficacy with these late stage drugs has been poor, at best demonstrating minimal improvements in PFS. In the EU, both Avastin and Yondelis have been approved on the basis of improvements in PFS alone. It is expected therefore, that those pipeline drugs that have demonstrated the most significant improvements in PFS - olaparib, Vynfinit and trebananib, will be approved in this territory. However even on approval, the lack of an overwhelming improvement in clinical benefit with these drugs, and their expected high cost will limit their sales. In the US, the improvement in PFS observed with Yondelis and Avastin, in the absence of any other clinical benefit with either drug, resulted in neither drug being approved by the FDA. In line with these rejections, the improvements in PFS alone, observed with the current late stage pipeline drugs, is expected to result in the failure of any drug to be approved in the US within the forecast period.

4. Description As a result the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9billion in 2020. Despite the poor results obtained with late stage pipeline drugs there is evidence of continued interest in the ovarian cancer market, with a high number of drug candidates in the current developmental pipeline, particularly at the Preclinical Phase. There is a wide range of novel molecular targets distributed amongst these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in other indications in oncology. Request for discount at: http://www.reportsandintelligence.com/purchase-enquiry/132440

5. Scope • A brief introduction to ovarian cancer, including the disease’s pathogenesis, risk factors and diagnosis. • In-depth analysis of the drug combinations used in the treatment of ovarian cancer, including analyses of their safety, efficacy, and place in the disease treatment algorithm. This includes a heat map comparing the drug combination in terms of safety and efficacy. • Comprehensive review of the pipeline for ovarian cancer therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes. • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.

6. Reasons to buy • Understanding the efficacy and safety of the current monotherapies and drug combinations used in the treatment of ovarian cancer, with an in-depth analysis of the disease treatment algorithm. • Understand the key signalling pathways and molecular targets currently inder investigation in drug development for ovarian cancer • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent. • Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic cancer therapeutics. • Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ovarian cancer therapeutics market.

7. Table Of Content 1 Table of Contents1 Table of Contents 31.1 List of Tables 61.2 List of Figures 72 Introduction 92.1 Disease Pathophysiology 92.1.1 Ovarian Cancer - A Group of Distinct Diseases 92.1.2 Ovarian Cancer is Highly Heterogenic, with Multiple Mutations and Affected Signaling Pathways 102.2 Symptoms and Diagnosis 122.3 Risk Factors 132.3.1 Age 132.3.2 Inherited Genetic Mutations 132.3.3 Greater Number of Lifetime Ovulations 142.3.4 Weight 142.3.5 Previous Medical Conditions 14 2.4 Treatment Algorithm 14

8. Table Of Content 2.4.1 Surgery 142.4.2 First-Line Chemotherapy 142.4.3 Maintenance Therapy 182.5 Recurrent Disease 203 Marketed Products 363.1 Carboplatin 363.2 Paclitaxel 373.3 Gemcitabine 383.4 Topotecan 403.5 Pegylated Liposomal Doxorubicin 413.6 Yondelis 423.7 Avastin 434 Product Pipeline 454.1 Overview of Pipeline by Phase and Route of Administration 45 4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target 474.2.1 Molecular Targets in the Developmental Pipeline 48

9. Table Of Content 4.3 Clinical Trials 534.3.1 Clinical Trial Duration 534.3.2 Clinical Trial Size 544.3.3 Failure Rate 574.3.4 Discussion 595 Late-Stage Drugs in Developmental Pipeline 615.1 Profiles 615.1.1 Niraparib 615.1.2 Olaparib 625.1.3 Abagovomab 64 Get full TOC at: http://www.reportsandintelligence.com/ovarian-cancer-therapeutics-in-major-developed-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies-market/table-of-contents

10. FOR MORE DETAILS Visit us at : http://www.reportsandintelligence.com/ovarian-cancer-therapeutics-in-major-developed-to-2020-late-stage-pipeline-focuses-on-improved-progression-free-surival-and-targeted-therapies-market Stay With Us: • TELEPHONE: Direct: +1 (617) 674-4143 • Toll Free: +1 (855) 711-1555E-MAIL: sales@reportsandintelligence.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States